Substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseases
US12344607B2 · kind B2 · utility
0Cited by
2References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 1, 2023 |
| Grant date | Jul 1, 2025 |
| Priority date | — |
| Expiry date | Aug 24, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides novel tetrahydropyran (THP)-substituted bicyclic pyrimidinedione compounds, including (6S,7S)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2H-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (shown below), that are useful for the treatment of hypertrophic cardiomyopathy (HCM), conditions associated with left ventricular hypertrophy, conditions associated with diastolic dysfunction, and/or symptoms associated thereof. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.